

SENOLYTICS

James L. Kirkland, MD, PhD
AFAR President

Unitary Theory of Fundamental Aging Mechanisms

Fundamental Aging Mechanisms

Inflammation (chronic, low-grade, sterile), Fibrosis
Macromolecular/Organelle Dysfunction (DNA, protein aggregates, autophagy, AGEs, lipotoxicity, mitochondria)
Stem Cell and Progenitor Dysfunction
Cellular Senescence



Phenotypes

Geriatric Syndromes:

Sarcopenia
Frailty
Immobility
MCI


Chronic Diseases:

Dementias
Cancers
Atherosclerosis
Diabetes
Osteoporosis
Osteoarthritis
Renal dysfunction
Blindness
Chronic lung disease

Decreased Resilience:


Infections
Delirium
Delayed wound healing
Slow rehabilitation
Chemotherapy toxicity
ICU Care

DNA Damage (telomere shortening, mutations, alkylating agents, radiation)
Oncogenes (*e.g.*, Ras, Myc)
Reactive Metabolites (ROS, ceramides, fatty acids, high glucose)
Mitogens/ IGF-1
Proteotoxic Stress (protein aggregation, unfolded protein response, mTOR)
Shear Stress, Hypoxic Stress, Hyperoxic Stress
Inflammation, Damage-Associated Molecular Pattern Proteins (DAMPs)
Pathogen-Associated Molecular Pattern Proteins (PAMPs)
Drugs: Nutlin3a, Alkylating Agents, Anthracyclines





Senescent Cells Accumulate in Human Adipose Tissue With Aging

Young




Old



4 younger (31 ± 5 y) and 4 older (71 ± 2 y) healthy male volunteers. *p<0.05




Transplanting Senescent Cells Causes Physical Dysfunction and Decreases Survival




Senescence
induced by
10 Gy
radiation

*Xu et al.,
Nature
Medicine,
2018*

Transplanting Senescent Cells Accelerates Death From All Causes




Cause of death




Xu *et al.*, Nature Medicine, 2018

Transplanted Senescent Cells Spread Senescence to Host Cells

Xu *et al.*, Nature Medicine, 2018



Transplantation of Old Cardiac Allografts Induces Cellular Senescence in Young Recipient Organs




Hearts from either young or old C57BL/6 (2 and 18 months) were transplanted to young syngeneic recipients. Liver and draining lymph nodes were collected from donors 30 days after engraftment, cut into slides, and co-stained for p16^{Ink4a}, p21^{Cip1}, and DAPI



Hypothesis-Driven Senolytic Drug Development

- 1) Senescent cells can resist apoptotic stimuli, implying increased pro-survival – anti-apoptotic defenses
- 2) In some respects, senescent cells are like cancer cells that do not divide, including apoptosis resistance and metabolic shifts


Hypothesis-Driven Senolytic Drug Development: Networks of Anti-Apoptotic Regulators Confer Resistance to Apoptosis in Senescent Cells



Pathways:
Ephrins/
dependence
receptors; PI3K δ /
Akt/ metabolic;
Bcl-2 (Bcl-xl,
Bcl-2, Bcl-w);
p53/ FOXO4/ p21/
serpine (PAI-1&2);
HIF-1 α ; HSP90

Discovered in May
2013; Aging Cell,
March, 2015; Nature
Commun, Sept., 2017

siRNA's Against Anti-Apoptotic Regulators Selectively Decrease Senescent Cell Viability




Radiation-induced
senescent cells

Selected from 39 pro-survival transcripts
targeted, 17 of which specifically eliminated
senescent cells, including Bcl-xL, leading to
our discovery that Navitoclax is senolytic

D Targets Senescent Human Preadipocytes, Q Targets Senescent HUVECs

Zhu *et al.*,
Aging Cell,
March, 2015



ATP Lite; validated by crystal violet; abdominal subcutaneous preadipocytes from 4 healthy kidney transplant donors; for HUVEC's N=5 replicates.

Routes to Discovering Senolytics

1st Generation

Mechanism-Based

Discovered by Identifying SCAPs and
Then Selecting Drugs with Known SCAP

Dasatinib **Geldanamycin**

Quercetin **Tanespimycin**

Fisetin **Alvespimycin**

Luteolin More being developed

Enzastaurin

Navitoclax (ABT263)

A1331852

A1155463

Piperlongumine

FOXO4-Related Peptide

Cardiac Glycosides

2nd Generation

Randomly Identified


Identified by Chance or with
High-Throughput Compound
Library Screens

Many being
developed

Other approaches:
Immunomodulators
CAR-T
Vaccines
SA β -gal-activated
toxins
Nanoparticle Toxins
Others


The first senolytics were discovered based on their mechanisms of action and targets. The next generation is being identified using random high-throughput approaches such as drug library screens

D+Q Clears Transplanted Luciferase-Expressing Senescent Preadipocytes




**SFFV Promoter-Luciferase; 10^5
Cells Transplanted/ Mouse**

**Xu *et al.*, Nature
Medicine, 2018**






**Non-senescent cell-
transplanted**



Senescent cell-transplanted


A Single Dose of Senolytics Alleviates Radiation-Induced Gait Disturbance for 7 Months





N=6-9 mice/
group;
* $P < 0.05$;
** $P < 0.001$

Zhu *et al.*,
Aging Cell
March, 2015

Senolytics Prevent and Alleviate Dysfunction Caused by Transplanting Senescent Cells into Middle-Aged Mice





Senolytics Decrease Senescent Cells and cf-mt-DNA Levels, Alleviate Systemic Hyper-Inflammatory Immune Responses, and Prolong Cardiac Allograft Survival



Iske *et al.*,
Nature
Commun,
2020

C57BL/6 mice were treated with D+Q or PBS prior to fully mismatched cardiac transplantation. Recipients were treated weekly with CTLA4-IG, a fusion protein of CLTA-4 and IgG that blocks the interaction of CD80/86 with CD28 on naive T cells. Allograft survival was monitored by daily palpation. N=at least 3 independent expts.

Targeting Senescent Cells Slows Death of Old Mice Infected with Mouse β -Coronavirus






Emerging Evidence for Benefits of Senolytics On:

Diabetes/ Obesity
Age-Related Lipodystrophy
Cardiac Dysfunction
Vascular Hyporeactivity/ Calcification/ AV Fistulae
Frailty/ Sarcopenia
Response to Chemotherapy/ Response to Radiation
Cancer
Sequellae of Bone Marrow Transplantation
Sequellae of Organ Transplantation
Myeloma/ MGUS
Cognition/ Alzheimer's/ Parkinson's/ ALS/ Anxiety
Renal Dysfunction
Osteoporosis/ Osteoarthritis/ Rheumatoid Arthritis/ Degenerated Discs
COPD/ Idiopathic Pulmonary Fibrosis/ Tobacco/ Hyperoxic Lung Damage
Hepatic Steatosis/ Liver Cirrhosis/ Primary Biliary Cirrhosis
Progerias
Critical Illness Myopathy
Pre-eclampsia/ Uterine Fibrosis/ Ovarian Involution
Cataracts/ Macular Degeneration/ Glaucoma
Prostatic Hypertrophy
Skin Disorders
Stem Cell Activation/ Progenitor Dysfunction
Lifespan
COVID-19


D+Q Clears Senescent Cells From Diabetic Subjects' Adipose Tissue



Abdominal subcutaneous adipose biopsies at baseline (BL) and 11 days after the last dose (PT) of a 3 day course of D+Q; N=9 subjects (paired T test)



ClinicalTrials.gov
identifier:
NCT02848131

D+Q Decreases Plasma SASP Factors in Patients with Diabetic Kidney Disease



Plasma SASP factors were assayed at baseline (Day 0) and after treatment (Day 14). Colors indicate fold change for each individual between Days 0 and 14 (post-treatment/ baseline value; N=9; p=0.003, composite score of differences (after-before) in z-scores of log-transformed values)



First-in-Human Trial of Senolytics: D+Q for Idiopathic Pulmonary Fibrosis



**No severe
adverse events**

9 doses/ 3 wks

**Functional
measures 5 days
after last dose**



**Justice *et al.*,
eBioMed.,
2019**

Selected Current and Planned Translational Geroscience Network Clinical Trials of Senolytics

Trial	Senolytic Agent	Notes	Status	Funding Agency	Site(s)	ClinicalTrials.gov Identifier (NCT)
AFFIRM: Alleviation by Fisetin of Frailty, Inflammation, and Related Measures in Older Women	Fisetin	Phase 2 Double-Blind, Placebo-Controlled. Gait Speed <0.6 M/sec	Recruiting	Benefactor	Mayo	03430037
AFFIRM-LITE: Alleviation by Fisetin of Frailty, Inflammation, and Related Measures in Older Adults	Fisetin	Phase 2 Double-Blind, Placebo-Controlled. Gait Speed ≥0.6 M/sec	Recruiting	Benefactor	Mayo	03675724
ALSENLITE: An Open-Label, Pilot Study of Senolytics for Alzheimer Disease	D+Q	Target Engagement; Double-Blind, Placebo-Controlled	Recruiting	Alzheimer's Association	Mayo	04785300
Pilot Study to Investigate the Safety and Feasibility of Senolytic Therapy to Modulate Progression of Alzheimer's Disease (SToMP-AD)	D+Q	Open Label Pilot Phase	Recruiting	UTHSCSA Internal Funding	UTHSCSA	04063124
Senolytic Therapy to Modulate the Progression of Alzheimer's Disease (SToMP-AD)	D+Q	Cognitive Function; Double-Blind, Placebo-Controlled	Active, Not yet recruiting	Alzheimer's Drug Discovery Foundation	Mayo, UTHSCSA, Wake Forest	04685590
Senescence in Chronic Kidney Disease	D+Q	Open Label	Recruiting; Pilot Study Published ^{89,90}	Benefactor	Mayo	02848131
Inflammation and Stem Cells in Diabetic and Chronic Kidney Disease	Fisetin	Double-Blind, Placebo-Controlled	Recruiting	Benefactor	Mayo	03325322
Hematopoietic Stem Cell Transplant Survivors Study (HTSS)	D+Q	Randomized; Parallel Assignment; Open-Label	Recruiting	Benefactor	Mayo	02652052
Senolytics to Improve Cognition and Mobility in Older Adults at Risk of Alzheimer's	D+Q	Single Arm, Open Label, Pre-Post Pilot Study	Recruiting	NIH	Harvard (Hebrew Rehab. Center)	Pending

Selected Current and Planned Translational Geroscience Network Clinical Trials of Senolytics

Trial	Senolytic Agent	Notes	Status	Funding Agency	Site(s)	ClinicalTrials.gov Identifier (NCT)
SENSURV: An Open-Label Intervention Trial to Reduce Senescence and Improve Frailty in Adult Survivors of Childhood Cancer	Fisetin; D+Q	Randomized, Open-Label	Active, Not yet recruiting	NIH	St. Jude (1° Site); Mayo (Assays)	04733534
IPF: Trial of Senolytics in Idiopathic Pulmonary Fibrosis	D+Q	Double-Blind, Placebo-Controlled	Planned (Open-Label Pilot Study Published ⁶⁰)	Pending	UTHSCSA; Wake Forest; Mayo	02874989 (Pilot Phase)
Targeting Cellular Senescence with Senolytics to Improve Skeletal Health in Older Humans	Fisetin; D+Q	Randomized; Parallel Assignment; Open Label	Recruiting	NIH	Mayo	04313634
Senolytic Drugs Attenuate Osteoarthritis-Related Articular Cartilage Degeneration: A Clinical Trial	Fisetin	Double-Blind, Placebo-Controlled	Recruiting	Office of Naval Research	Steadman Clinic (1° Site); Mayo (Assays)	04210986
COVID-FIS, A Study of Fisetin for Skilled Nursing Facility Residents with COVID-19	Fisetin	Double-Blind, Placebo-Controlled	Recruiting	NIH	Mayo	04537299
COVID-FISETIN: Pilot in SARS-CoV-2 of Fisetin to Alleviate Dysfunction and Inflammation	Fisetin	Double-Blind, Placebo-Controlled	Recruiting	Benefactor	Mayo	04476953
COVFIS-HOME: COVID-19 Pilot Study of Fisetin to Alleviate Dysfunction and Disease Complications	Fisetin	Double-Blind, Placebo-Controlled	Recruiting	Benefactor	Mayo	04771611



Ax1 Mission Overview

~1 day of launch and transfer to ISS

~8 days on ISS

~1 day to return and re-enter Earth

Launch and land off the coast of Florida

- Project 1: Impact of Near Earth Low Gravity Space Travel on Fundamental Aging Processes. An Exploratory Human Minimal Risk Study
- Project 2: Impact of Near Earth Low Gravity Space Travel on Fundamental Aging Processes. Does the Low Gravity Environment Cause Cultured Human Cells to Undergo Senescence?



Conclusions

- Persistent senescent cells cause inflammation, fibrosis, progenitor cell dysfunction, spread of senescence, and multiple disease- and age-related disorders
- The target of senolytics is senescent cells, not a single molecule or pathway
- Senolytics attenuate tissue inflammation and fibrosis, improve function, and reduce rejection after transplanting organs from old individuals
- “Hit and run” intermittent senolytic treatment may be effective
- Senolytics delay or alleviate multiple chronic diseases, improve tissue regeneration, and enhance healthspan in mice
- These agents could lead to interventions for humans that delay, prevent, or alleviate senescence- and age-related conditions – if clinical trials continue to demonstrate effectiveness and low toxicity



Acknowledgements

T Tchkonja
R Petersen
I Scarisbrick
V Lowe
J Chen
S Tullius
L Larsson
T Pirtskhalava
N Giorgadze
T Thomou
Y Zhu
M Xu
M Stout
A Palmer
L Prata Langhi
C Inman
K Johnson
M Mahlman
T von Zglinicki
D Jurk
J Passos
M Ogradnik
N LeBrasseur
M Schaefer
S Khosla
R Pignolo
J Westendorf
H Fuhrmann-Stroissnigg
L Niedernhofer
P Robbins
F Sierra
E Hadley
L Hickson
S Hashmi
J Farr
M Weivoda
J Netto
U Smith
D Allison
K Nath
V Garovic

K Ejima
T Evans
J Sexton
T Volkman
E Wissler-Gerdes
J Campisi
G Ellison
F Kuipers
G Kuchel
J Newman
J Justice
N Musi
G Armstrong
K Ness
J Miller
C Roos
E Chini
M Wentworth
T Harris
J Wren
M Jensen
C Conover
M Masternak
Y Ikeno
J Kopchick
D Berryman
A Oberg
N Barzilai
S Austad
J Walston
M Oursler
S Kritchevsky
A Nambiar
J van Deursen
D Baker
S Hayman
U Tripathi
S Chaib
A Xue
M Weigand

**AG13925,
AG31736,
AG41122,
AG44396,
AG61456,
AG62413,
AG72301
Kogod Aging Center,
The Connor Group,
Noaber Foundation,
The Ryans,
Ted Nash Foundation,
AFAR,
Alzheimer's Association,
Alzheimer's Drug
Discovery Foundation
Perry and Doris Teeter
Foundation**